Logotype for Everest Medicines Limited

Everest Medicines (1952) investor relations material

Everest Medicines H1 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Everest Medicines Limited
H1 2025 earnings summary29 Aug, 2025

Executive summary

  • Revenue for the six months ended 30 June 2025 rose 48% year-over-year to RMB 446.1M, driven by NEFECONⓇ and XERAVAⓇ sales, expanded market access, and international expansion.

  • NEFECONⓇ achieved full approval in all licensed Asian territories, NRDL inclusion in China, and rapid sales ramp-up, with over 20,000 new patients in H1 2025.

  • Advanced R&D pipeline with progress in mRNA cancer vaccines, in vivo CAR-T, and EVER001, plus positive clinical data and regulatory clearances.

  • Strategic investment in I-Mab, becoming its largest shareholder, to enhance oncology collaboration.

  • Successful share/top-up placement in August 2025 raised HKD 1.6B (RMB 1.6B), strengthening the cash position for R&D and commercialization.

Financial highlights

  • Revenue increased 48% year-over-year to RMB 446.1M in 1H 2025, mainly from NEFECONⓇ and XERAVAⓇ.

  • Gross margin (cash/excluding amortization) was 76.4%; reported gross margin was 67.1% due to NRDL price reduction.

  • Non-IFRS/adjusted net loss narrowed by 31% year-over-year to RMB 146.9M–147M, reflecting improved operational efficiency.

  • Cash and equivalents stood at RMB 1.6B as of June 30, 2025, bolstered by recent financing.

  • R&D expenses decreased to RMB 195.2M, while distribution and selling expenses rose to RMB 314.7M due to expanded commercial activities.

Outlook and guidance

  • Full-year 2025 revenue guidance set at RMB 1.6B–1.8B, with NEFECONⓇ expected to contribute RMB 1.2B–1.4B.

  • Targeting operational profitability in 2H 2025, potentially earlier than previously guided.

  • VELSIPITYⓇ NDA approval expected in early 2026 in Mainland China, with ongoing prelaunch and manufacturing activities.

  • Overseas NEFECONⓇ sales to grow in 2026 as reimbursement in Taiwan and South Korea is implemented.

  • Multiple clinical and regulatory milestones expected in 2H 2025 for mRNA cancer vaccines and in vivo CAR-T platform.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Everest Medicines earnings date

Logotype for Everest Medicines Limited
H2 202525 Mar, 2026
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Everest Medicines earnings date

Logotype for Everest Medicines Limited
H2 202525 Mar, 2026

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Everest Medicines Limited is a biopharmaceutical company focused on the development, manufacturing, and commercialization of innovative medicines. The company specializes in therapies for infectious diseases, autoimmune disorders, and oncology. It partners with global biotechnology firms to bring advanced treatments to markets in China and other Asian regions. The company is headquartered in Shanghai, China, and its shares are listed on the Hong Kong Stock Exchange (HKEX).

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage